An Update on Prenatal Diethylstilbestrol Exposure and High-Grade Squamous Intraepithelial Lesions of the Lower Genital Tract
Related Experiment Video
Updated: Jul 2, 2025

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
Rebecca Troisi1, Kimberly Bertrand, Elizabeth E Hatch
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland; Boston University School of Medicine and Slone Epidemiology Center at Boston University, and Boston University School of Public Health, Boston, and the Department of Molecular, Cell, and Cancer Biology, University of Massachusetts, Chan Medical School, Worcester, Massachusetts; the Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas; the Department of Pathology, Duke University Medical Center, Durham, North Carolina; and Public Health, Muskie School of Public Service, University of Southern Maine, Portland, Maine.
Abstract:
Women with prenatal diethylstilbestrol exposure are excluded from less frequent cervical cancer screening because of their increased neoplasia risk. We report the results of a prospective follow-up study of prenatal diethylstilbestrol exposure and lower genital tract high-grade (grade 2 or higher) squamous intraepithelial lesions (HSIL). The age-adjusted risk of HSIL among diethylstilbestrol-exposed women (n=4,062) was higher than among the diethylstilbestrol unexposed (n=1,837) through age 44 years (hazard ratio 2.03, 95% CI, 1.31-3.14) but not age 45 years or older. Elevated HSIL risk remained higher in diethylstilbestrol-exposed women, after accounting for frequency of cervical cancer screening. Compared with unexposed women, HSIL risk was higher among women with earlier gestational and high-dose diethylstilbestrol exposure. These data confirm the appropriateness of more frequent screening among diethylstilbestrol-exposed women through age 44 years. Whether those aged 45 years or older should continue to have increased screening will require careful weighing of possible risks and benefits.
Related Concept Videos
Sexually Transmitted Infections
Teratogenicity

